HK Stock Market Move | IMMUNEONCO-B(01541) rose over 9% in the afternoon. The phase III clinical trial protocol for IMM0306 has obtained approval from the Center for Drug Evaluation (CDE).

IMMUNEONCO-B (01541) rose by more than 9% in the afternoon, and as of the time of writing, it had risen by 7.98% to HK$7.31 with a turnover of HK$107.04 million. On the news front, YimingAngke announced at noon that the company had received approval from the National Medical Products Administration Drug Evaluation Center for the phase III clinical study protocol of IMM0306 in combination with lenalidomide for the treatment of relapsed/refractory follicular lymphoma, signaling the acceleration of the development of innovative therapies for relapsed/refractory follicular lymphoma. IMM0306 is the world's first CD47 and CD20 dual-targeting bispecific molecule to enter clinical trials. It can block the "don't eat me" signal, activate macrophages and NK cells, preferentially bind to CD20 rather than CD47, effectively eliminate malignant B cells, and reduce toxicity to a minimum, thereby improving treatment efficacy. The company owns global intellectual property and commercialization rights for IMM0306.